AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15603006 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (both groups)
Number of subjects: 109
Study 11498066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral crystalline cyanocobalamin (3000 microg or 5000 microg once a week for at least 3 months)
Number of subjects: 10
Study 9405901 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 199
Study 7635783 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR-6 (6 fractions of 7 Gy per fraction)
Number of subjects: 92
Study 7635783 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR-4 (4 fractions of 8 Gy per fraction)
Number of subjects: 92
Study 7635783 — intervention group
Group type: COMPARATOR
Intervention: LDR (40 Gy in two split courses)
Number of subjects: 92
Study 2705632 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-glucosaminoglycan sulfate
Number of subjects: 30
Study 325301 — intervention group
Group type: EXPERIMENTAL
Intervention: Guancydine (21 mg/kg body weight for 7 to 18 days)
Number of subjects: 9
Study 325301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during a control period averaging 14 days)
Number of subjects: 9
Study 325301 — intervention group
Group type: EXPERIMENTAL
Intervention: Guancydine
Number of subjects: 9
Study 31414865 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus parental involvement (CBT-PI)
Number of subjects: 136
Study 31414865 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 136
Study 31414865 — intervention group
Group type: COMPARATOR
Intervention: Social activity
Number of subjects: 136
Study 31339919 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced peer education and routine screening for family planning needs plus expanded non-condom FP method availability in drop-in centers (DIC).
Number of subjects: 719
Study 31339919 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 719
Study 28056936 — intervention group
Group type: EXPERIMENTAL
Intervention: choline-stabilized orthosilicic acid (ch-OSA)
Number of subjects: 211
Study 28056936 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 211
Study 24796764 — intervention group
Group type: EXPERIMENTAL
Intervention: CC/IUI (Clomiphene Citrate/Intrauterine Insemination)
Number of subjects: 154
Study 24796764 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH/IUI (Follicle Stimulating Hormone/Intrauterine Insemination)
Number of subjects: 154
Study 24796764 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate IVF (In Vitro Fertilization)
Number of subjects: 154
Study 24796764 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 154
Study 24796764 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 154
Study 22429881 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained eaters
Number of subjects: 111
Study 22429881 — intervention group
Group type: COMPARATOR
Intervention: Unrestrained eaters
Number of subjects: 111
Study 20164585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 927
Study 24692821 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 19
Study 24692821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15670788 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype V3‐V4 (G‐C)
Number of subjects: 785
Study 15670788 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B gene
Number of subjects: 785
Study 15670788 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B serum concentration
Number of subjects: 785
Study 12765846 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid supplementation (3.6g n‐3 fatty acids/day containing 2.4 g of EPA and DHA)
Number of subjects: 150
Study 12765846 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules containing olive oil
Number of subjects: 150
Study 10580781 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups (hormone therapy)
Number of subjects: 5
Study 10580781 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 5
Study 7562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference-instructed group
Number of subjects: 5
Study 7562389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study 7562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli from different sources
Number of subjects: 5
Study 7562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental association with stimulus behavior
Number of subjects: 5
Study 7562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit trait inferences after several days
Number of subjects: 5
Study 2366533 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min exercise at VO2 20% below VT
Number of subjects: 22
Study 2366533 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise at VO2 20% below VT
Number of subjects: 22
Study 2366533 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 min exercise at VO2 20% below VT
Number of subjects: 22
Study 39387 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (Cordanum)
Number of subjects: 224
Study 31312252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression with linear interaction
Number of subjects: 0
Study 31312252 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable Fractional Polynomials for Interaction (MFPI)
Number of subjects: 0
Study 31312252 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Partial-Likelihood Bootstrap (LPLB)
Number of subjects: 0
Study 31312252 — intervention group
Group type: COMPARATOR
Intervention: Categorization of continuous covariates (splitting at the median, quartiles, or optimal split)
Number of subjects: 0
Study 27817246 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 30
Study 27817246 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength followed by endurance training (ST-END)
Number of subjects: 30
Study 27817246 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance followed by strength training (END-ST)
Number of subjects: 30
Study 27817246 — intervention group
Group type: COMPARATOR
Intervention: No training (CON)
Number of subjects: 30
Study 27817246 — intervention group
Group type: EXPERIMENTAL
Intervention: All training interventions
Number of subjects: 30
Study 27817246 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) and Endurance followed by strength training (END-ST)
Number of subjects: 30
Study 27817246 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance followed by strength training (END-ST) and Strength training (ST)
Number of subjects: 30
Study 26232241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg (AOM 400)
Number of subjects: 295
Study 26232241 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate once-monthly (PP)
Number of subjects: 295
Study 22415652 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stents (SEMSs)
Number of subjects: 60
Study 22415652 — intervention group
Group type: COMPARATOR
Intervention: Plastic tube stents (PSs)
Number of subjects: 60
Study 22010090 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-enriched hydroxyapatite (MHA)
Number of subjects: 15
Study 22010090 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine bone (PB)
Number of subjects: 15
Study 22010090 — intervention group
Group type: COMPARATOR
Intervention: Control (unfilled sockets)
Number of subjects: 15
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in D/P-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in P/S-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: Apparent Diffusion Coefficient (avADC) in D/P-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: Apparent Diffusion Coefficient (avADC) in P/S-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: N-acetylaspartate (NAA)/creatine-phosphocreatine complex (Cr) in D/P-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: Choline (Cho)/Cr and myoinositol (mI)/Cr ratios in D/P-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: COMPARATOR
Intervention: Choline (Cho)/Cr and myoinositol (mI)/Cr ratios in P/S-PALS
Number of subjects: 32
Study 20014653 — intervention group
Group type: EXPERIMENTAL
Intervention: FA values in D/P-PALS with increasing disability
Number of subjects: 32
Study 20014653 — intervention group
Group type: EXPERIMENTAL
Intervention: avADC values in D/P-PALS with increasing disability
Number of subjects: 32
Study 17560404 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14992983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 91
Study 14992983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 14992983 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 91
Study 14992983 — intervention group
Group type: COMPARATOR
Intervention: Placebo and guided self-help
Number of subjects: 91
Study 11208039 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dialysate composition
Number of subjects: 0
Study 11208039 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate composition
Number of subjects: 0
Study 9150318 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d.
Number of subjects: 674
Study 9150318 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg b.i.d.
Number of subjects: 674
Study 9150318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study 8352096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 35
Study 8352096 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 35
Study 3112025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (250 mg/kg body weight, intravenous route, days 3 to 13)
Number of subjects: 26
Study 3112025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin
Number of subjects: 26
Study 3112025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pseudomonas immunoglobulin)
Number of subjects: 26
Study 29746282 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 82
Study 29746282 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate 500 mg daily
Number of subjects: 82
Study 27039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in relative abundance of insulin-like growth factor binding proteins (IGFBPs) and subclasses of apolipoprotein (Apo) and transthyretin
Number of subjects: 249
Study 27039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in relative abundance of 13 proteins predominantly involved in inflammation
Number of subjects: 249
Study 27039242 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-acid labile subunit, orosomucoid 1 (ORM1), Apo C-I, pyruvate kinase isoenzymes M1/M2
Number of subjects: 249
Study 27039242 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 proteins involved in inflammation (including ORM1, α-1-antichymotrypsin, reticulocalbin 1, and 3 components of the complement cascade)
Number of subjects: 249
Study 24683583 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ tissue‐engineered graft containing 54 ± 38 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group A)
Number of subjects: 40
Study 24683583 — intervention group
Group type: COMPARATOR
Intervention: In situ tissue‐engineered graft containing 1,012 ± 752 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group B)
Number of subjects: 40
Study 23221658 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application training program
Number of subjects: 0
Study 23221658 — intervention group
Group type: COMPARATOR
Intervention: Control group (handout only)
Number of subjects: 0
Study 20682875 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (three daily 400-mg doses)
Number of subjects: 195
Study 20682875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 18646538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group A (health education intervention, two questionnaire surveys before and after intervention)
Number of subjects: 270
Study 18646538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group B (health education intervention, one questionnaire survey after intervention)
Number of subjects: 270
Study 18646538 — intervention group
Group type: COMPARATOR
Intervention: Control group C (general hygienic knowledge education, two questionnaire surveys before and after intervention)
Number of subjects: 270
Study 18646538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group A
Number of subjects: 270
Study 18646538 — intervention group
Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 270
Study 18646538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group B
Number of subjects: 270
Study 15923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (15 mg spansules twice daily)
Number of subjects: 232
Study 15923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tablets twice daily)
Number of subjects: 232
Study 15923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg tablets twice daily)
Number of subjects: 232
Study 15923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (all treatments)
Number of subjects: 232
Study 12730546 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic knee tape
Number of subjects: 18
Study 12730546 — intervention group
Group type: COMPARATOR
Intervention: Neutral knee tape
Number of subjects: 18
Study 12730546 — intervention group
Group type: COMPARATOR
Intervention: Untaped
Number of subjects: 18
Study 10994404 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg adenosine
Number of subjects: 31
Study 10994404 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg adenosine
Number of subjects: 31
Study 10323120 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia in the anterior mucobuccal fold
Number of subjects: 0
Study 10323120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30%)
Number of subjects: 0
Study 10323120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1462581 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg propranolol retard in one dose daily for 10 days
Number of subjects: 25
Study 1462581 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 25
Study 6370974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 124
Study 6370974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 30374831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate and 0.2% sodium hyaluronate treatment
Number of subjects: 56
Study 30374831 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 56
Study 30374831 — intervention group
Group type: COMPARATOR
Intervention: Neutral solution (placebo)
Number of subjects: 56
Study 30374831 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 30053978 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation (PR) for 3 weeks
Number of subjects: 383
Study 27099245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (52 g)
Number of subjects: 27
Study 27099245 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (65 g)
Number of subjects: 27
Study 27099245 — intervention group
Group type: COMPARATOR
Intervention: Sucralose (0.1 g)
Number of subjects: 27
Study 25263326 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry treatment (300 g of blueberry) + smoking
Number of subjects: 16
Study 25263326 — intervention group
Group type: COMPARATOR
Intervention: Smoking treatment (one cigarette)
Number of subjects: 16
Study 25263326 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (300 mL of water with sugar) + smoking
Number of subjects: 16
Study 22215709 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified serum IgG from patients with β2 and/or M3 receptor agonistic activity
Number of subjects: 20
Study 22215709 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of IgG from patients
Number of subjects: 20
Study 22215709 — intervention group
Group type: COMPARATOR
Intervention: Sequential addition of β‐blocker propranolol
Number of subjects: 20
Study 22215709 — intervention group
Group type: COMPARATOR
Intervention: Sequential addition of NO synthase inhibitor N(G)‐nitro‐L‐arginine methyl ester
Number of subjects: 20
Study 19464312 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal and mid-profile pose faces
Number of subjects: 3
Study 19464312 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile view faces
Number of subjects: 3
Study 19464312 — intervention group
Group type: EXPERIMENTAL
Intervention: Half face (one eye visible in frontal and profile view)
Number of subjects: 3
Study 19464312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-frontal faces (both eyes visible)
Number of subjects: 3
Study 19464312 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper region of a face
Number of subjects: 3
Study 19464312 — intervention group
Group type: COMPARATOR
Intervention: Lower half faces
Number of subjects: 3
Study 17453366 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise regimen (12-week training including guided aerobic exercise once a week and home exercise sessions twice a week)
Number of subjects: 30
Study 17453366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 15339760 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor rehabilitation (n = 21)
Number of subjects: 64
Study 15339760 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor rehabilitation with abdominal muscle training (n = 23)
Number of subjects: 64
Study 15339760 — intervention group
Group type: COMPARATOR
Intervention: Control non-pelvic floor rehabilitation (n = 20)
Number of subjects: 64
Study 11676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 103
Study 11676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial fundoplication
Number of subjects: 103
Study 11676232 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic group
Number of subjects: 103
Study 11676232 — intervention group
Group type: COMPARATOR
Intervention: Various surgical techniques (simple closure of His angle, Hill operation, Belsey Mark IV technique, Angelchik prosthesis)
Number of subjects: 103
Study 9739036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral food supplements for 4 weeks in addition to hospital food
Number of subjects: 42
Study 9739036 — intervention group
Group type: COMPARATOR
Intervention: Only hospital food for 4 weeks
Number of subjects: 42
Study 8037025 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal averaging
Number of subjects: 30
Study 8037025 — intervention group
Group type: COMPARATOR
Intervention: Phase reordering
Number of subjects: 30
Study 3196076 — intervention group
Group type: EXPERIMENTAL
Intervention: metaproterenol sulfate in aerosolized saline solution
Number of subjects: 20
Study 3196076 — intervention group
Group type: COMPARATOR
Intervention: placebo (aerosolized saline only)
Number of subjects: 20
Study 3196076 — intervention group
Group type: COMPARATOR
Intervention: no pretreatment
Number of subjects: 20
Study 29294357 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.17%
Number of subjects: 54
Study 29294357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 54
Study 27417199 — intervention group
Group type: EXPERIMENTAL
Intervention: Crew resource management team training intervention with SBAR tool for structured communication during patient referrals.
Number of subjects: 0
Study 26634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored anterior transvaginal mesh surgery (ATVM)
Number of subjects: 104
Study 26634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored posterior transvaginal mesh surgery (PTVM)
Number of subjects: 104
Study 26634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic studies
Number of subjects: 104
Study 26634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life improvement
Number of subjects: 104
Study 26634203 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 104
Study 23394141 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal and infant intake of n-3 PUFAs and oily fish, reduced parental smoking, and reduced indoor dampness during pregnancy and the children's first 2 years of life.
Number of subjects: 0
Study 23394141 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (not specified in detail).
Number of subjects: 0
Study 21084796 — intervention group
Group type: EXPERIMENTAL
Intervention: Synaptose Complex KB220Z™
Number of subjects: 17
Study 21084796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18534567 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 12
Study 18534567 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 12
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemarcol together with Vitremer
Number of subjects: 90
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 90
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit W
Number of subjects: 90
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate together with AH26
Number of subjects: 90
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 90
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemarcol together with Super‐EBA
Number of subjects: 90
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 90